Funding the physical frontier — the brain, the factory, fusion's fuel, and orbit

Precision raised an oversubscribed $250M Series D at a ~$1B valuation, co-led by Pershing Square and the Ackman Oxman Institute; total funding is now $430M.

Its Layer 7 cortical interface — FDA-cleared in 2025 — has been used in 100+ patient procedures across 18 institutions.

Backers include ARK Invest, Mubadala Capital, B Capital, and Hitachi Ventures; the capital funds a push toward a permanent, fully implantable device.

A crossover investor like Pershing Square backing a BCI signals the field is de-risking in big-capital eyes.

Precision's minimally invasive approach competes with Neuralink directly on safety and a faster regulatory path.

It's the clearest sign yet of a BCI funding wave — the New York Times flagged the surge as Paradromics and others advance in parallel.

Precision (private) is now among the best-capitalized pure-play BCI companies, with a cleared device and a unicorn valuation.

The surface-electrode thesis offers a differentiated risk profile from invasive peers.

Risk: a permanent implant is still years from approval, and BCI commercialization timelines remain long and capital-intensive.

The IFR's World Robotics 2026 report put the global installed base above 5 million industrial robots, with the US now the second-largest market.

Maven Robotics (Santa Clara) confirmed a $100M Series A (RoboStrategy-led), with Gulf capital from Shorooq and Presight (a G42 company) joining.

Maven's wheeled, two-armed robots run 16-hour shifts at 99%+ uptime, handling mixed-case palletizing and tote handling.

Robotics has crossed from pilots to installed infrastructure — the adoption curve is now measured in millions.

General-purpose robots (vs. single-task arms) are where capital is concentrating, a bet on flexibility.

Gulf sovereign capital is moving aggressively into physical AI, extending its frontier-tech push into robotics.

Maven (private) is a US-built play on the warehouse-automation market it sizes at $80B.

Global robotics VC topped $18.8B in H1 2026 — well-funded, but increasingly crowded.

Risk: industrial buyers demand extreme reliability, and many general-purpose entrants won't clear that bar — China is already cooling its humanoid-robot IPO rush.

StandardX raised a £10M seed (co-led by Vsquared Ventures and East X Ventures; Brevan Howard Macro Venture, firstminute capital, and UKI2S participating).

Its accelerator-based refinery aims to produce rare isotopes at commercial scale — including tritium for fusion.

The company has signed agreements with fusion developers and will build its first site in London.

Tritium scarcity is one of fusion's least-discussed but hardest bottlenecks — you can't fuel a plant you can't supply.

A dual medicine-and-fusion platform spreads risk across two high-value markets; cancer-therapy isotopes are also critically scarce.

It's another picks-and-shovels bet — selling to the whole fusion industry rather than racing to build a reactor.

StandardX (private, early) is a rare supply-chain play on fusion, with near-term medical-isotope revenue.

Signed fusion offtake agreements provide demand validation unusual at seed stage.

Risk: isotope production is capital-, facility-, and regulation-heavy, and commercial fusion demand is still years out.

The US EXIM Bank approved a $468M direct loan under its Make More in America initiative to scale Astranis's California production.

Astranis builds MicroGEO satellites, has five in orbit, and reports a $1.2B+ backlog.

The facility follows a $450M equity-and-debt raise in May; total capital raised exceeds $1.2B (backers include a16z, BlackRock, and Fidelity).

Sovereign connectivity — countries wanting their own satellites rather than relying on shared constellations — is a fast-growing market.

Government export financing behind a private space firm signals space is now treated as strategic industrial infrastructure.

Astranis's vertically integrated model (it designs, builds, and operates) is a bet on controlling the whole stack.

Astranis (private) offers exposure to GEO connectivity and sovereign demand, distinct from LEO mega-constellations.

The EXIM facility is non-dilutive capital that de-risks a manufacturing scale-up against a real backlog.

Risk: this is debt, not equity — it adds leverage, and GEO faces intensifying competition from Starlink and other LEO players.

Architecture as a carrier of health — buildings designed from the ground up around the biology of the people inside them

Technology as an amplifier of ancient wisdom — biometric data and natural systems integrated at the design level

Wellbeing as a measurable asset — longevity science embedded in every structural and environmental decision

Community as a protective layer — a curated global ecosystem of health-conscious individuals

IP as scalable value — a multi-platform ecosystem for designing human life, built to grow with the science